AzTrials
AzTrials

Depression DisorderNCT07333027

Lonely in Depression

An observational study of Depression Disorder and Loneliness, run by Friedrich-Alexander-Universität Erlangen-Nürnberg at 2 sites in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this prospective study is to better understand the link between loneliness and depression in the inpatient psychiatric treatment of depression. It aims to answer: Do lonely and not lonely persons benefit the same way from inpatient depression treatment? Is loneliness a clinical relevant factor in inpatient… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Depression Disorder, Loneliness
How many people
200 participants
Where
2 sitesGermany
Study dates
5 Feb 2026to Sep 2027
How long will I take part?
3 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Individuals who are admitted for inpatient treatment at one of the two psychiatric clinics in Erlangen (university hospital, community hospital), Germany, either electively or as an emergency case, due to depressive symptoms.

Who may be able to join

  • primary diagnosis of depression according to ICD-10 (F32 or F33), as diagnosed by a physician or clinical psychologist in conjunction with the M.I.N.I. Mini-International Neuropsychiatric Interview diagnostic tools
  • inpatient elective or emergency admission to one of the two psychiatric clinics; - age over 18 years
  • sufficient understanding of spoken and written German
  • informed voluntary consent

Who cannot join

  • a current lack of capacity to provide consent (e.g., pronounced psychotic symptoms, stuporous depressive syndrome, and thought constriction to suicidality)
  • previous participation in the study
  • pregnancy or breastfeeding
  • inpatient stay of less than 7 days, even if the patients initially met the inclusion criteria.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Franziska Sonnauer, Dr. med., M.Sc. contact

00499131-8534597

franziska.sonnauer@uk-erlangen.de

Germany2 sites, 2 recruiting
  • Friedrich-Alexander-Universität Erlangen-Nürnberg

    Erlangen, Bavaria, 91054

    Franziska Sonnauer, Dr. med., 00499131-8534597, einsamkeit-depression.ps@uk-erlangen.de

    Franziska Sonnauer, Dr. med.

    Recruiting
  • Bezirkskliniken Mittelfranken, Clinic for Psychiatry, Addiction, Psychotherapie and Psychosomatic Medicine

    Erlangen, Bavaria, 91056

    Franca Laura Fries, Dr. med., 004991317535353, Franca.Fries@bezirkskliniken-mfr.de

    Maksym Druzenko, 004991317535353, Maksym.Druzenko@bezirkskliniken-mfr.de

    Not yet recruiting

Other trials in Germany

About this study

Official title: Effects of Loneliness in the Treatment of Depression

The goal of this prospective study is to better understand the link between loneliness and depression in the inpatient psychiatric treatment of depression. It aims to answer:

Do lonely and not lonely persons benefit the same way from inpatient depression treatment? Is loneliness a clinical relevant factor in inpatient treatment of depression? What are the underlying biopsychosocial mechanisms?

Participants will be asked to do some

  • self-report questionnaires
  • clinical interview
  • biosampling (blood, saliva, stool) at three main measurement timepoints (1. begin of inpatient treatment, 2. day of discharge, 3. three months after discharge).
Read the detailed description

Loneliness and depression are widespread and severely debilitating health conditions. Notably, loneliness and depression are closely intertwined, with individuals suffering from depression being particularly vulnerable to loneliness. However, little is known regarding the clinical significance of loneliness in the treatment of depression and the biopsychosocial mechanisms underlying this association.

To examine the clinical relevance of the interplay between loneliness and depression, a prospective, noninterventional longitudinal design will be adopted. The study will be performed at the University Hospital and the community hospital in Erlangen, Germany. Every patient admitted to the hospital with depressive symptoms is eligible for screening according to the inclusion and exclusion criteria. Three main measurement points (T0, T1, and T2) and brief interim measurements conducted at two-week intervals (t0.1 to t0.X and t1.1-t1.6) will be utilized. After screening and clinical interviews, participants will complete the baseline measurements (T0). Thereafter, each participant will adhere to an individual period corresponding to the duration of that specific patient's inpatient stay at the clinic until the second measurement is obtained (T1). Follow-up will occur three months after T1.

Given that the effect sizes of the interaction between loneliness and depression in a clinical population are currently unknown, the sample size for this study was determined based on considerations of practicability and the population generalizability of the obtained results, as well as statistical plausibility.

To ensure the external validity of the results, it is important that both severely lonely depressive patients and less lonely depressive patients, as well as different disease trajectories and patient characteristics (e.g., age, sex, and number of comorbidities), can be identified. A sample size of approximately 200 participants is expected to ensure sufficient heterogeneity. This sample size is practically feasible due to the fact that, even when considering an inclusion rate of 50% and a dropout rate of 30% for the primary diagnosis of depression at the University Hospital and the community hospital in Erlangen, the recruitment potential clearly exceeds the target number of cases within an estimated period of two years.

Without the knowledge of which measured level of loneliness at baseline represents a strong level of loneliness and which measured level represents a weak level of loneliness in a depressed patient population, a median split of loneliness at baseline will be performed to calculate the statistical significance of the interaction between loneliness and depression in the inpatient and follow-up course (T0, T1, and T2). To detect a significant interaction effect of a mixed analysis of variance (ANOVA), when considering an α error of 0.05, a power of 0.9 (1-β error probability) and a correlation value among repeated measures of 0.5 for the groups defined as highly lonely and slightly lonely groups, the number of cases was calculated by using G*Power Version 3.1.9.7. Assuming a small effect size (f= 0.10), the desired sample size would be determined at n= 214 individuals; moreover, assuming a medium effect size (f= 0.25), the sample size would be n= 36 individuals. This indicates that there is statistical plausibility for detecting interaction effects between loneliness and depression with the target number of cases.

Eligibility screening and clinical diagnostic screening, along with interviews, are conducted by study physicians. Depression is assessed during a clinical interview (MADRS) by the patient's treatment team, which also determines when the patient will be discharged from the hospital. All of the self-report assessments are collected by the patients themselves by using the REDCap online survey application. Biosampling will be exclusively performed among participants recruited at the University Hospital to ensure methodologically consistent and rapid processing. Routine clinical data are primarily extracted from clinical documentation systems and consolidated prior to analysis (similar to other data sources).

Given that the study design does not permit definitive causal conclusions to be determined regarding the direction of effects, the findings are expected to provide valuable insights and relevant implications. In particular, the following insights can be obtained: (1) a report on whether more or less lonely patients receive equal benefits from inpatient multimodal depression treatment; (2) insights into changes in loneliness during and after depression treatment; (3) important findings regarding the shared and nonshared biopsychosocial mechanisms underlying loneliness and depression; and (4) the effects of loneliness and depression with respect to secondary outcomes, including quality of life and suicidality.

Keywords
loneliness, depression, prospective, biosampling, clinical
Medical subject headings
Depression

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Depression (symptom severity)

    Montgomery-Åsberg Depression Rating Scale (MADRS) (10 Items, each item rated 0-6 points, minimum 0 points, maximum 60 points, higher scores indicate greater severity of depressive symptoms)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  2. Loneliness

    3 Item UCLA Loneliness Scale (3-Item UCLA) (3 items, each item rated 1-3 points, minimum 3 points, maximum 9 points, higher scores indicate greater loneliness)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  3. Depression

    Patient Health Questionnaire, 9-Item Depression Scale (PHQ-9) (9 Items, each item rated 0-4 points, minimum 0 points, maximum 27 points, higher scores indicate greater severity of depression)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  4. Loneliness

    6-Item short scales for Loneliness, De Jong Gierveld Loneliness Scale (6-Item DJGLS) (6 Items, each item rated 1-3 points, before the total score is calculated, the items are dichotomized, thus resulting in a sum score ranging from 0 to 6, wherein scores of 0-1 indicate no loneliness, 2-4 indicate moderate loneliness, and 5-6 indicate severe loneliness)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

Secondary outcomes (7)
  1. Social Support

    Fragebogen zur Sozialen Unterstützung (F-SoZ-U 14) (14 Item shortend form, each item rated 0-4 points, minimum 0 points, maximum 56 points, higher total scores indicating higher levels of perceived social support)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  2. Inpatient treatment duration

    in days

    Measured: Baseline/T0 (day 1 of inpatient stay) to T1 (end of inpatient stay, normally 7 up to 50 weeks).

  3. Quality of life in self-report

    World Health Organization-Five Well-Being Index (WHO-5) (5 Items, each item rated 0-5 points, minimum 0 points, maximum 25 points, the total score (0-25) is transformed to a scale ranging from 0 to 100, with scores ≤50 indicating diminished well-being and higher scores representing higher well-beeing)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  4. Social Network measure (newly designed for this study)

    As there is no culture and language adapted version of a social network indice available an adapted and German-translated version is used to capture participants' social interaction partners during the prior two weeks. The questionnaire was newly developed, with item content informed by existing validated scales (Cohen Social Network Index (SNI), Lubben Social Network Scale (LSNS), Berkman - Social Network/Integration).

    Via the use of a yes/no response format, participants indicated whether they had personal or telephone contact with each of the following: (1) spouse or partner, (2) own children, (3) parents or parent-like figures, (4) other relatives (e.g., siblings, uncles, or aunts), (5) friends, (6) neighbors, (7) colleagues, (8) people known through voluntary activities, (9) in-laws (parents, sons, or daughters-in-law), and (10) members of their social group (e.g., community, congregation, sports, or music clubs).

    Higher total scores indicate greater social connectedness.

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  5. General health status

    Short Form 12 Health Survey (SF-12) (12 Items, Items rated 0-1, 1-3 and 1-5 and 1-6 scores represent eight dimensions of physical and mental well-beeing with two composite scores, items are recodet, z-transformed and normed, higher values indicate better health)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  6. Social Anxiety

    Social Phobia Inventory (SPIN) (17 Items, each item rated 0-4 points, minimum 0 points, maximum 68 points, higher scores indicate greater severity of social anxiety, three subscales are available (fear 6 items, avoidance 7 items, physiological distress 4 items))

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

  7. Somatic Symptom Burden

    13-Item Somatic Symptom Severity Scale of the Patient Health Questionnaire (PHQ-13) (13 Items, each item rated 0-2 points, minimum 0 points, maximum 34 points, higher values indicating more somatic symptoms)

    Measured: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2026
  2. Study start5 Feb 2026
  3. Primary completionSep 2027 (estimated)
  4. Study completionSep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
200 participants (estimated)
Target duration
3 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07333027
Sponsor's protocol ID
25-435-B
Status last verified
Jun 2026
First submitted
2 Dec 2025
Last updated
15 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: IPD used in the results publication No final desicion has been made as several partners are involved and feasibility and regulatory requirements are still under review.

Publications

  • Sonnauer F, Fries FL, Druzenko M, Kastner UW, Muhle C, Kornhuber J. Clinical relevance of loneliness in the treatment of depression: study protocol for a naturalistic prospective longitudinal study. Front Psychiatry. 2026 Jul 24;17:1827062. doi: 10.3389/fpsyt.2026.1827062. eCollection 2026.

    PubMed 42568550

Questions about this trial

What is this clinical trial studying?

An observational study of Depression Disorder and Loneliness, run by Friedrich-Alexander-Universität Erlangen-Nürnberg at 2 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Franziska Sonnauer, Dr. med., M.Sc. (00499131-8534597, franziska.sonnauer@uk-erlangen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Depression (symptom severity) (time frame: Baseline/T0 (recruitment, normally day 1 of inpatient stay and maximum of day 7), T1 (end of inpatient stay ± 7 d, normally 7 days up to 50 weeks), Follow-Up/T2 (three months after clinical discharge ± 7 d); measured T0 to T1 and T0 to T2 and T1 to T2). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07333027, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in